Powered by

Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update

Feb 27, 2019 - PR Newswire
Financial Results

PR Newswire

 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on the company's recent achievements and anticipated upcoming milestones.

"2018 was a transformative year marked by significant progress in adv...